StockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

Stock analysts at StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research note issued on Tuesday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Stock Performance

NASDAQ ADXS opened at $0.67 on Tuesday. Ayala Pharmaceuticals has a 12 month low of $0.51 and a 12 month high of $1.95. The company’s 50 day moving average is $0.75 and its two-hundred day moving average is $0.76.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.